Raphael Pharmaceutical Inc.

RAPH

Raphael Pharmaceutical Inc.

RAPH

Insider Sentiment (TTM):

Last Purchase:2009-12-17Last Sale:-Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:N/AInstitutional Shares Owned:N/AShares Outstanding:N/AInstitutional Ownership Pct.:N/A

Earnings Market Reaction:

Filing Date:2026-08-14Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Related Party	-	0	0	0	0	0	0	0	-0	0	-	-
Assets Current
Assets
Cash And Cash Equivalents At Carrying Value	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets Current	0	-	0	0	0	0	0	0	0	0	0	0
Assets Current	0	0	0	0	0	0	0	0	0	0	0	0
Finite Lived Intangible Assets Net	-	-	-	-	-	-	-	-	0	0	0	0
Assets Noncurrent
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	-	-	0	-
Assets	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities And Stockhold…
Liabilities Current
Accounts Payable And Other Accrued Liabilities Cur…	1	1	1	0	0	0	1	1	0	0	0	0
Short Term Borrowings	-	-	-	-	-	-	0	-	-	-	-	-
Notes Payable Current	-	-	-	-	-	-	0	-	-	-	0	0
Liabilities Current	2	2	1	1	1	1	1	1	0	0	0	0
Stockholders Equity
Stockholders Equity Note Subscriptions Receivable	-	-	-	-	-	-	-	-	-	-	-0	-
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	9	9	9	8	8	8	8	8	8	8	7	7
Retained Earnings Accumulated Deficit	-11	-10	-10	-10	-10	-9	-9	-8	-8	-8	-7	-7
Stockholders Equity	-2	-2	-1	-1	-1	-1	-1	-1	-0	-0	0	-0
Liabilities And Stockholders Equity	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Common Stock Shares Authorized	50	50	21	50	21	21	21	50	50	21	21	21
Common Stock Shares Issued	20	20	20	20	20	20	19	19	19	19	19	18
Shares Outstanding	20	20	20	20	20	20	19	19	19	19	19	18

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	0.00%	0.00%	0.00%	-	-	-	-	-	-	-	-	-
2025	-78.00%	-25.00%	-25.00%	0.00%	81.82%	354.55%	0.00%	40.00%	40.00%	0.00%	0.00%	0.00%
2024	64.00%	65.00%	65.00%	0.00%	0.00%	-84.24%	0.00%	53.85%	284.62%	0.00%	0.00%	-78.00%
2023	-	-	-	-	-	-	-2.52%	-2.52%	-2.52%	0.00%	0.00%	64.00%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	0.00	0.00	0.03	0.00	0.03	0.11	0.03	0.07	0.30	0.77	1.80	0.84
Quick Ratio	0.00	0.00	0.03	0.00	0.03	0.11	0.03	0.07	0.30	0.77	1.80	0.84
Working Capital	-1.89M	-1.66M	-1.44M	-1.27M	-1.05M	-736.00K	-744.00K	-618.00K	-292.00K	-106.00K	105.00K	-76.00K
Leverage & Debt
Debt to Equity	-1.00	-1.00	-1.04	-1.01	-1.03	-1.13	-1.04	-1.08	-1.44	-4.43	1.23	-6.37
Interest Coverage TTM	309.00	347.67	-	-	-	-	-	-	-	-	-	-
Debt Ratio	270.29	555.00	28.04	181.57	35.93	8.89	28.48	13.08	3.27	1.29	0.55	1.19
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	0.05	0.05	0.07	0.07	0.08	0.07	0.08	0.06	0.08	0.04	-0.00	0.07
Free Cash Flow Per Share TTM	-0.01	-0.00	-0.01	-0.01	-0.01	-0.03	-0.03	-0.03	-0.05	-0.05	-0.07	-0.08
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-33.42%	-22.82%	-15.80%	31.92%	0.75%	75.63%	-8,538.89%	-7.41%	-243.10%	-164.66%	-97.70%	-269.67%
EPS Growth (1Y)	-35.24%	-24.92%	-19.58%	25.70%	-4.13%	66.59%	-7,654.41%	-18.58%	-223.43%	-155.45%	-98.03%	-255.41%
Valuation Metrics
P/E TTM	28.82	26.18	21.40	5.60	10.00	14.04	3.20	29.06	21.09	23.39	-928.72	14.71
P/B TTM	-14.99	-17.00	-19.10	-6.21	-14.05	-26.74	-6.54	-50.09	-106.26	-180.74	156.23	-224.94
Market Cap	28.25M	28.25M	27.37M	7.85M	14.72M	19.63M	4.86M	30.86M	30.82M	18.62M	16.72M	16.87M
Enterprise Value	28.25M	28.25M	27.33M	7.85M	14.70M	19.58M	5.21M	30.82M	30.70M	18.33M	16.52M	16.61M
Calculated Values
Free Cash Flow TTM	-180.00K	-45.00K	-210.00K	-109.00K	-172.00K	-569.00K	-533.00K	-559.00K	-980.00K	-977.00K	-1.20M	-1.39M
Net Debt	-1.00K	-1.00K	-45.00K	-3.00K	-20.00K	-50.00K	359.00K	-40.00K	-120.00K	-287.00K	-192.00K	-259.00K
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2009-12-17Purchase

Owner: Ofir, Guy

Title: President

Shares: 990,000

Price/Share: $0.06

Value: $59,400.00

Shares Owned: 4,865,800

Relationship: Director,Officer,TenPercentOwner

Ownership: Indirect

2009-09-22Purchase

Owner: Ofir, Guy

Title: President

Shares: 1,000,000

Price/Share: $0.15

Value: $150,000.00

Shares Owned: 21,724,153

Relationship: Director,Officer,TenPercentOwner

Ownership: Direct

2008-12-02Purchase

Owner: Ofir, Guy

Title: President

Shares: 200,000

Price/Share: $0.06

Value: $12,000.00

Shares Owned: 20,320,000

Relationship: Director,Officer,TenPercentOwner

Ownership: Direct

2008-11-24Purchase

Owner: Ofir, Guy

Title: President

Shares: 15,000

Price/Share: $0.08

Value: $1,200.00

Shares Owned: 20,120,000

Relationship: Director,Officer,TenPercentOwner

Ownership: Direct

2008-10-03Purchase

Owner: Ofir, Guy

Title: President

Shares: 34,800

Price/Share: $0.15

Value: $5,220.00

Shares Owned: 3,539,800

Relationship: Director,Officer,TenPercentOwner

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2009-12-17	Ofir, Guy	Director,Officer,TenPercentOwner	President	Indirect	Purchase	990,000	0.06	$59,400.00	4,865,800	5
2009-09-22	Ofir, Guy	Director,Officer,TenPercentOwner	President	Direct	Purchase	1,000,000	0.15	$150,000.00	21,724,153	4
2008-12-02	Ofir, Guy	Director,Officer,TenPercentOwner	President	Direct	Purchase	200,000	0.06	$12,000.00	20,320,000	4
2008-11-24	Ofir, Guy	Director,Officer,TenPercentOwner	President	Direct	Purchase	15,000	0.08	$1,200.00	20,120,000	4
2008-10-03	Ofir, Guy	Director,Officer,TenPercentOwner	President	Indirect	Purchase	34,800	0.15	$5,220.00	3,539,800	4/A
2008-09-30	Ofir, Guy	Director,Officer,TenPercentOwner	President	Indirect	Purchase	43,500	0.15	$6,525.00	3,568,500	4
2008-09-29	Ofir, Guy	Director,Officer,TenPercentOwner	President	Indirect	Purchase	5,000	0.15	$750.00	3,525,000	4/A
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

No institutional ownership data available.

Raphael Pharmaceutical Inc. (RAPH) — SEC Financial Statements & Analysis

Raphael Pharmaceutical Inc. (RAPH) is a medicinal chemicals & botanical products company, incorporated in NV. Raphael Pharmaceutical Inc. trades on OTC as: RAPH. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Raphael Pharmaceutical Inc. reported a Debt-to-Equity ratio of -1.00x, a Price-to-Book (P/B) ratio of -14.99x (TTM), at a market cap of $28.25M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: -1.00x
P/B TTM: -14.99x
Market Cap: $28.25M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Raphael Pharmaceutical Inc. in?

Raphael Pharmaceutical Inc. (RAPH) operates in the Medicinal Chemicals & Botanical Products industry.

What is RAPH's market cap?

Raphael Pharmaceutical Inc. (RAPH) has a market capitalization of $28.25M as of 2026-06-30.

What is RAPH's P/E ratio?

Raphael Pharmaceutical Inc. (RAPH)'s trailing twelve month P/E ratio is 28.82x as of 2026-06-30.

What exchange does RAPH trade on?

Raphael Pharmaceutical Inc. (RAPH) trades on the OTC.

Where is Raphael Pharmaceutical Inc. incorporated?

Raphael Pharmaceutical Inc. is incorporated in NV.